Every day, a new health technology company claims to reinvent healthcare. Which ones actually improve patient outcomes, and which are just repackaging old inefficiencies with better user interfaces? In Healthtech Talks with Fexingo, Lucas and Luna cut through the hype to examine the real economics and clinical evidence behind digital health, telemedicine, and medical software. They analyze specific companies — from telemedicine platforms like Teladoc to AI diagnostic tools from Aidoc — dissecting their business models, regulatory hurdles, and adoption curves. Lucas brings a journalist's precision to revenue numbers, clinical trial data, and policy changes (e.g., FDA digital health guidance, CMS telehealth reimbursement rules). Luna challenges assumptions about scalability, patient privacy, and equity of access, grounded in real-world case studies like Babylon Health's rise and fall or the integration of Epic Systems across hospital networks. Each episode focuses on a single topic: how remote patient monitoring platforms affect readmission rates, whether AI scribes actually reduce physician burnout, why some digital therapeutics succeed while others fail FDA clearance. This show is for healthcare executives, venture investors, clinicians evaluating tools, and policy analysts who want substance over slogans. Lucas and Luna don't do 'will robots replace doctors' speculation; they ask: What is the unit economics of a virtual primary care visit? Which medical specialties are most ripe for software disruption? And when will the evidence catch up to the pitch deck?

Support FexingoRSS Feed